tert-butyl 6-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamido)hexylcarbamate | 1255535-12-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: tert-butyl 6-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamido)hexylcarbamate
• 英文别名: tert-butyl 6-(7-hydroxy-coumarin-4-acetamido)hexylcarbamate；tert-butyl N-[6-[[2-(7-hydroxy-2-oxochromen-4-yl)acetyl]amino]hexyl]carbamate
• CAS: 1255535-12-6
• 化学式: C₂₂H₃₀N₂O₆
• 分子量: 418.49
• InChiKey: HZQNAKOPTQCACU-UHFFFAOYSA-N

物化性质

• 沸点：
  678.7±55.0 °C(Predicted)
• 密度：
  1.192±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl 6-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamido)hexylcarbamate 、 2,3,4,6-四乙酰氧基-alpha-D-吡喃糖溴化物 在 四丁基硫酸氢铵 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.83h， 以1.4 g的产率得到(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-(2-(6-(tert-butoxy carbonylamino)hexylamino)-2-oxoethyl)-2-oxo-2H-chromen-7-yloxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate
  参考文献：
  名称：

  Design and synthesis of substrates for newborn screening of Maroteaux–Lamy and Morquio A syndromes

  摘要：

  In continued efforts to develop enzymatic assays for lysosomal storage diseases appropriate for newborn screening laboratories we have synthesized novel and specific enzyme substrates for Maroteaux-Lamy (MPS VI) and Morquio A (MPS IVA) diseases. The sulfated monosaccharide derivatives were found to be converted to product by the respective enzyme in blood from healthy patients but not by blood from patients with the relevant lysosomal storage disease. The latter result shows that the designed substrates are highly selective for the respective enzymes. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.080
• 作为产物：
  描述：

  7-羟基香豆素-4-乙酸 、 N-Boc-1,6-己二胺 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以52%的产率得到tert-butyl 6-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamido)hexylcarbamate
  参考文献：
  名称：

  Design and synthesis of substrates for newborn screening of Maroteaux–Lamy and Morquio A syndromes

  摘要：

  In continued efforts to develop enzymatic assays for lysosomal storage diseases appropriate for newborn screening laboratories we have synthesized novel and specific enzyme substrates for Maroteaux-Lamy (MPS VI) and Morquio A (MPS IVA) diseases. The sulfated monosaccharide derivatives were found to be converted to product by the respective enzyme in blood from healthy patients but not by blood from patients with the relevant lysosomal storage disease. The latter result shows that the designed substrates are highly selective for the respective enzymes. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.080

文献信息

• [EN] MASS SPECTROMETRIC COMPOSITIONS AND METHODS FOR LYSOSOMAL STORAGE DISEASE SCREENING<br/>[FR] COMPOSITIONS UTILISÉES EN SPECTROMÉTRIE DE MASSE ET MÉTHODES DE DÉPISTAGE DE LA MALADIE LYSOSOMALE
  申请人：GELB MICHAEL

  公开号：WO2012027612A1

  公开（公告）日：2012-03-01

  Provided herein are substrates, internal standards, enzymatic assays, and screening methods pertaining to the analysis of various lysosomal storage diseases. In particular, mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome), mucopolysaccharidosis IVA (Morquio A Syndrome), Fabry Syndrome, Pompe Syndrome, and mucopolysaccharidosis I (Hurler) (MPS IH) Syndrome may be analyzed, particularly with respect to the screening of patients.
• Design and synthesis of substrates for newborn screening of Maroteaux–Lamy and Morquio A syndromes
  作者：Trisha A. Duffey、Tanvir Khaliq、C. Ronald Scott、Frantisek Turecek、Michael H. Gelb

  DOI：10.1016/j.bmcl.2010.08.080

  日期：2010.10

  In continued efforts to develop enzymatic assays for lysosomal storage diseases appropriate for newborn screening laboratories we have synthesized novel and specific enzyme substrates for Maroteaux-Lamy (MPS VI) and Morquio A (MPS IVA) diseases. The sulfated monosaccharide derivatives were found to be converted to product by the respective enzyme in blood from healthy patients but not by blood from patients with the relevant lysosomal storage disease. The latter result shows that the designed substrates are highly selective for the respective enzymes. (c) 2010 Elsevier Ltd. All rights reserved.